Dynavax Technologies Corporation
Dec 1, 2016

Dynavax to Webcast Cancer R&D Day on December 9, 2016

BERKELEY, CA -- (Marketwired) -- 12/01/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will hold a Research and Development (R&D) Day in New York City next week where it will showcase its immuno-oncology program. The event, which is for institutional investors, will be webcast live and can be found in the Investor section of the company's website at www.dynavax.com.

The webcast of the presentations and Q&A will begin at 8:30 a.m. EST on Friday, December 9, 2016 and is scheduled to conclude at 11:00 a.m. EST. Presentations will be made by senior executives of Dynavax and will also feature two world-renowned experts in immuno-oncology:

About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com.

Michael Ostrach
Chief Financial Officer
Email contact

Source: Dynavax Technologies

News Provided by Acquire Media